Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
... were presented at the International Congress for epilepsy
Budapest, Hungary. Patients not controlled ... in vital need of
better seizure control."
is one of the most common neurological diseases, ... partial-onset seizures and their treatment
is one of the most common neurological diseases, ...
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
... need for many people living with uncontrolled epilepsy
- Vimpat(R) offers hope to people with epilepsy
who still have uncontrolled partial onset ... of partial-onset seizures in people with epilepsy
who are 17 years and older. Vimpat(R) will be ...
VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
... WASHINGTON, May 12 /PRNewswire/ -- The epilepsy
Foundation recently announced findings that show ... or generic-to-generic.
See video from the epilepsy
Foundation at: ... said Eric R. Hargis, president and CEO of the epilepsy
The study, which surveyed more ...
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
... Studies Presented at American epilepsy
Society Annual Meeting
ATLANTA, Dec. 9 ... at the 62nd annual meeting of the American epilepsy
Society (AES) in Seattle.
Keppra XR was ... at 1-866-822-0068 (press 9).
Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures
... of the 32nd Annual
Meeting of the American epilepsy
Results from two identical ...
About Partial Onset Seizures and epilepsy
is one of the most common disorders of the ...
Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy
... in adult
patients with refractory partial-onset epilepsy
when a 600 mg or 900 mg dose
was added to a ... which helps control
neuronal excitability. In epilepsy
patients, brain cells can become overly
excited, ... seizures.
"Approximately 30 percent of epilepsy
patients are not well-controlled
New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy
... with existing anti-epileptic
is one of the most common neurological diseases ... of life was analysed using the
Quality of Life epilepsy
Inventory-31 (QOLIE-31) scale. There was ... About partial seizures and their treatment
is one of the most common neurological diseases, ...
Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
... MD, Department
of Neurology, Johns Hopkins epilepsy
Center, Baltimore. "In this study,
short-term ... of partial onset seizures in adults with epilepsy
currently under review.
Applications for marketing authorization for lacosamide in epilepsy
supported by data from three clinical trials ...
Status of the E2007 (perampanel) Development Program
... and Focus on Neuropathic Pain and epilepsy
TOKYO, April 11 /PRNewswire/ -- ... is preparing for global Phase III
studies for epilepsy
and conducting two Phase II studies for ... focus
resources on two other ongoing indications, epilepsy
and neuropathic pain,
both of which have ...
Keppra XR(TM) Extended-Release Tablets Filed with the FDA
... of partial onset seizures in
adults with epilepsy
has been accepted for filing by the U.S. Food and ... to bringing new and
innovative therapies to the epilepsy
community," said Iris Loew-Friedrich,
MD, PhD, ... without the limitations of twice daily
therapies with more convenient dosing schedules ...
UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
... onset seizures in patients with
and was generally well tolerated," said ... as adjunctive
therapy in 158 refractory epilepsy
patients, 12 to 70 years of age, with
partial ... one in ten
patients with refractory partial onset epilepsy
achieved seizure freedom,"
said Dr. Jukka ...
New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
... as adjunctive therapy for patients
with partial epilepsy
with or without secondary generalization. ... were observed in either
treatment group. About epilepsy epilepsy
is defined by recurrent unprovoked seizures, or ...
New Research Shows: Neurofeedback is an 'Evidence-Based' Treatment for ADHD
... brain activity. This method was initially
discovered for the treatment of epilepsy
and from 1976 investigated further
for the treatment of ADHD. This ... for
each disorder. For example, a meta-analysis of EEG biofeedback in epilepsy
published in the same issue of EEG and Clinical Neuroscience ...
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
... as early as week two of the study. LGS is a severe
form of generalized epilepsy
that develops in early childhood and is
characterized by multiple types of ... said the study's lead
author Tracy Glauser, MD, Director, Comprehensive epilepsy
Cincinnati Children's Hospital Medical Center, Ohio. ...
Cyberonics Provides Update on Depression Post-Approval Study
... The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy
and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the ...
Astrocytes Help Separate Man From Mouse
... makes the brain so interesting."
To do the study, the team studied human brain tissue taken from 30 people who had had surgery, mostly to treat epilepsy
or brain tumors. They compared the astrocytes in human brains to those in mice and rats. In addition to the findings above, the team noted additional ...
Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
... being developed for the
treatment of motor fluctuations or "off episodes" in Parkinson's disease and
Acute Repetitive Seizures ("ARS") in refractory epilepsy
Richard de Souza, CEO of Archimedes, said: "Both these trials have
generated exciting results, highlighting the quality ...
Brain Waves Show Sound Processing Abnormalities in Autistic Children
... brain waves change with every sensation, thought and activity. It's like watching a movie of the brain in real time."
Typically used for epilepsy
evaluation, MEG can also be used to identify timing abnormalities in the brains of patients with autism.
"We found that signatures of autism ...
Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
twins conjoined at the head without neurological damage.
The hospital also provides treatment programs including dedicated
and sleep disorders centers, one of the nation's leading
adolescent AIDS programs, treatment for chronic conditions such as asthma
and diabetes, as ...
Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008
... company engaged in the discovery and development of novel
drug targets for the treatment of cancer and neurological diseases such as
and depression. The company's proprietary
SIGMACEPTOR(TM) Discovery Platform involves the rational design of drug
compounds that fulfill specific ...
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
... Inc., focuses exclusively on
providing solutions that improve neurological health. The company currently
markets products for Alzheimer's disease, epilepsy
and acute and preventive
migraine treatment. In conjunction with internal and external research
partners, Ortho-McNeil Neurologics continues to ...
Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
... acids in cardiovascular disease. Amarin's CNS development
pipeline includes programs in myasthenia gravis, Huntington's disease,
Parkinson's disease, epilepsy
and memory. Amarin is listed in the U.S. on
the NASDAQ Capital Market ("AMRN").
The information contained in this document is ...
TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
... development and management of clinical care and medical education policy for 29 affiliated hospitals. In addition, he was President of the epilepsy
Society of Southern New York. Dr. Tuchman is a frequent speaker about neuroscience topics at academic meetings.
"There's a growing body ...
Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
... within a 24-hour period in adults and a 12-hour
period in children. ARS, also called seizure clusters, occurs in a small
subset of patients with epilepsy
who regularly experience breakthrough
seizures in flurries or clusters despite treatment with a regimen of
anti-epileptic drugs. ARS is a rare ...
Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
... of acute migraine, our preclinical and
clinical data demonstrate potential utility across a range of pain
conditions, as well as diseases such as epilepsy
and anxiety. These
exciting results from the UCSD researchers further reinforce our belief in
the versatility of this first-in-class compound." ...
Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
developed by Kyorin Pharmaceutical, Ono Pharmaceutical and LG Life
Sciences. Fourth is a drug for one of the most severe forms of epilepsy
Gastaut Syndrome or LGS), affecting approximately 5% of the children who
have the disease. Eisai's rufinamide, licensed from Novartis, is ...
Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2
Study Data in Neurology
... to improve the management of
patients whose epilepsy
is not controlled by current medications,"
said ... and Safety Trials for Partial Onset epilepsy
two large, pivotal Phase 3 trials that ... safety and
efficacy of retigabine in refractory epilepsy
patients who are
receiving one, two or three ...
UCB Announces Positive Top-Line Phase III Results for Keppra as
Adjunctive Therapy for Partial Onset Seizures in Paediatric
Patients from One Month to Less than Four Years of Age
... prevalent neurological conditions. The
effects of epilepsy
on a child's psychological and social
development ... of age and older with idiopathic
(IGE). Keppra® tablets and oral solution
are ... of
age and older with idiopathic generalized epilepsy
primary generalized tonic-clonic ...
New Data Shows Once a Day Lamictal XR is Effective in Treating
Patients with Partial Seizures
... as add-on
treatment in patients with partial epilepsy
with and without
secondary generalization. ... seizure frequency among the
Epilepsy, defined by recurrent unprovoked ... cause of epilepsy
is unknown. According to the epilepsy
Foundation, more than three
million Americans of ...
Neurologix to Present at the Third Annual C.E. Unterberg Towbin
Emerging Growth Conference
... efforts are focused on gene therapy
for treating Parkinson's disease, epilepsy
neurodegenerative and metabolic disorders. Neurologix's ... disease and with additional trials in that indication
and in epilepsy
Marc Panoff, 201-592-6451
Icagen Terminates Phase III ASSERT Study
... an agreement with the McNeil
Pediatrics Division of McNeil-PPC, Inc., a subsidiary of Johnson &
- lead compounds for epilepsy
and neuropathic pain, for which the
Company is conducting preclinical studies;
- a lead compound for atrial fibrillation, for which the ...
Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results
of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's
Investigational Drug to Treat Cocaine and Methamphetamine Addiction
Vigabatrin has been marketed over the past decade in more than
30 countries under the brand name Sabril(R) as a secondary
treatment for adult epilepsy
and as a primary treatment for the
management of infantile spasms, known as West Syndrome.
Commenting on today's news and the Company's product ...
Neurologix Announces Publication of Landmark Gene Therapy Study
Demonstrating Safety and Statistically Significant Improvement in
Patients With Advanced Parkinson's Disease
... nervous system utilizing gene therapies. The
Company's initial development efforts are focused on gene therapy
for treating Parkinson's disease, epilepsy
neurodegenerative and metabolic disorders. Neurologix's core
technology, "NLX," is currently in the clinical development stages,